TELO — Telomir Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1971532 ·
Last close
$1.23
Market Cap
$84.59M
52W High
$2.09
52W Low
$0.89
ADV30
67,633
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -1,764,676 | -1,721,528 | 5,365,904 | 5,170,286 | 332,424 |
| Mar 2026 | 0 | — | -1,041,336 | -990,947 | 5,789,536 | 5,560,511 | 827,310 |
| Dec 2025 | 0 | — | -2,134,681 | -2,061,193 | 7,341,361 | 7,286,670 | 1,427,991 |
| Sep 2025 | 0 | — | -1,146,476 | -1,102,294 | 7,402,117 | 7,329,298 | 422,807 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-4,598,566
Investing CF
—
Financing CF
$9,756,078
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.30
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-42,001,010
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-9,223,115
Pretax Income TTM
$-9,224,324
Interest Exp TTM
$1,209
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -10,538,849 | -10,413,205 | 7,341,361 | 1,427,991 | 5,913,370 | -3,688,188 |
| Dec 2024 | 0 | -12,242,174 | -16,532,716 | 1,324,005 | 680,968 | 643,037 | -5,070,428 |
| Dec 2023 | 0 | -3,942,048 | -13,071,864 | 4,773,768 | 1,335,564 | 3,438,204 | -3,859,796 |
| Dec 2022 | 0 | -854,147 | -854,147 | 48,730 | 986,008 | -937,278 | -468,661 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.28
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ACET | Adicet Bio, Inc. | $84.44M | $9.02 | — |
| RACC | Research Alliance Corp III | $84.90M | $10.92 | — |
| ONCY | ONCOLYTICS BIOTECH INC | $86.71M | $0.68 | — |
| RVRC | Revium Rx. | $86.84M | $1.43 | — |
| RANI | Rani Therapeutics Holdings, Inc. | $87.61M | $0.76 | — |
News headlines (Yahoo Finance, 1h cache)
Telomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD)
2026-09-17 12:30 · Yahoo
Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model
2026-06-15 12:00 · Yahoo
Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease
2026-05-20 12:00 · Yahoo
Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)
2026-04-24 13:00 · Yahoo
Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer
2026-03-31 12:00 · Yahoo
Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models
2026-09-14 12:00 · Yahoo
Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models
2026-08-10 12:00 · Yahoo
Telo Genomics Announces Study with University of Athens to Advance Next-Generation MRD Risk Stratification in Multiple Myeloma
2026-04-14 11:00 · Yahoo
Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer
2026-04-30 12:00 · Yahoo
Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models
2026-01-05 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.